Fate Therapeutics
FATE
#8182
Rank
โ‚ฌ0.28 B
Marketcap
2,48ย โ‚ฌ
Share price
1.25%
Change (1 day)
153.06%
Change (1 year)

EPS for Fate Therapeutics (FATE)

EPS in 2026 (TTM): -0,93ย โ‚ฌ

According to Fate Therapeutics 's latest financial reports the company's current EPS (TTM) is -0,95ย โ‚ฌ. In 2025 the company made an earnings per share (EPS) of -1,01ย โ‚ฌ an increase over its 2024 EPS that were of -1,44ย โ‚ฌ.

EPS history for Fate Therapeutics from 2014 to 2026

Annual EPS

Year EPS Change
2026 (TTM)-0,93ย โ‚ฌ-7.63%
2025-1,01ย โ‚ฌ-29.88%
2024-1,44ย โ‚ฌ
2022-2,55ย โ‚ฌ30.49%
2021-1,95ย โ‚ฌ7.21%
2020-1,82ย โ‚ฌ45.45%
2019-1,25ย โ‚ฌ19.17%
2018-1,05ย โ‚ฌ17.65%
2017-0,89ย โ‚ฌ-3.77%
2016-0,93ย โ‚ฌ-12.4%
2015-1,06ย โ‚ฌ-3.97%
2014-1,10ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Becton Dickinson
BDX
2,89ย โ‚ฌ-402.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-0,50ย โ‚ฌ-47.71%๐Ÿ‡บ๐Ÿ‡ธ USA
PTC Therapeutics
PTCT
-2,04ย โ‚ฌ 113.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
5,88ย โ‚ฌ-715.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Avidity Biosciences
RNAM
-3,66ย โ‚ฌ 283.49%๐Ÿ‡บ๐Ÿ‡ธ USA